바이러스 여과 시장 규모, 점유율, 동향, 예측 : 제품별, 용도별, 최종 용도별, 지역별(2025-2033년)

The global virus filtration market size reached USD 4.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.8 Billion by 2033, exhibiting a growth rate (CAGR) of 8.04% during 2025-2033. The rising occurrences of global health crises, the growing need for mass production of biopharmaceuticals under tight schedules, and the growing investments in the development of new medicines, therapies, and vaccines are among the key factors driving the market growth.

Virus filtration is a critical step in the biopharmaceutical manufacturing process aimed at ensuring the safety and purity of medicinal products, including vaccines, antibodies, and biologics. This method is employed to remove viral contaminants that could be harmful to human health. It is especially essential in the production of parenteral medications, which are introduced directly into the body and thus require high purity standards. Typically, specialized membrane filters with defined pore sizes are used to capture and remove viruses. These filters are designed to allow the passage of the desired product while effectively trapping viral particles. The process is rigorously validated before implementation, and periodic testing is performed to confirm its effectiveness. Furthermore, it serves as a robust safeguard in pharmaceutical manufacturing, enhancing product safety and compliance with regulatory requirements.

The global market is majorly driven by the escalating occurrence of global health crises such as pandemics and widespread viral outbreaks. This highlights the importance of this filtration technique to ensure the safety of medical supplies and pharmaceuticals. During such times, there is an exponential increase in the demand for vaccines and other therapeutic agents. This demand necessitates the mass production of biopharmaceuticals under tight schedules, without compromising on safety. Therefore, this is positively influencing the market. Along with this, the rise of contract manufacturing organizations (CMOs) in the biopharmaceutical industry is another significant factor contributing to the growth of the market. In addition, the escalating investments in the development of new medicines, therapies, and vaccines, which inherently require these processes for safety and compliance are also significantly supporting the market.

Virus Filtration Market Trends/Drivers:

Increasing demand for biopharmaceuticals

One of the significant market drivers for the virus filtration industry is the growing demand for biopharmaceuticals such as monoclonal antibodies, recombinant proteins, and vaccines. These complex molecules are often derived from living cells, making them susceptible to viral contamination. Along with this, the rising prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders is impacting the market. This increase in demand places a burden on manufacturers to produce biopharmaceuticals that meet stringent safety and quality criteria. Virus filtration becomes an indispensable step in this scenario, as it is crucial for ensuring the purity and safety of these products. Regulatory bodies are imposing strict guidelines for viral clearance, further emphasizing the importance of these technologies. As more biopharmaceuticals enter the market or undergo clinical trials, the need for virus filtration services is accelerating correspondingly, thereby driving the industry forward.

Continual advancements in technology and research

Technological advancements in the field of filtration membranes and methods are significantly impacting the growth of the virus filtration industry. Along with this, the development of more efficient, scalable, and cost-effective filtration systems is making it easier for pharmaceutical companies to integrate these solutions into their existing production lines. Innovations in nanotechnology and material science are leading to filters with higher efficacy and better throughput capabilities, thus enabling more rapid and reliable virus removal. As research and development efforts continue in filtration technology, companies operating in this domain are increasing the adoption of the technology. This technological progress elevates the standard of pharmaceutical manufacturing and serves as a strong market driver for the global market.

An enhanced focus on regulatory compliance and quality assurance

Compliance with regulatory standards is a requirement and a market driver for the virus filtration industry. Agencies have specific guidelines about the viral safety of biologically-derived medicinal products. These guidelines often necessitate multiple steps for viral clearance, including virus filtration. Meeting these regulatory expectations is paramount for pharmaceutical companies to obtain product approvals and maintain market credibility. Given the dire consequences of viral contamination, ranging from delayed product launches to legal liabilities, the emphasis on regulatory compliance acts as a compelling force for the adoption of virus filtration technologies. Moreover, the industry benefits from this heightened focus on quality assurance, making it an essential component in the biopharmaceutical manufacturing value chain.

Virus Filtration Industry Segmentation:

Breakup by Product:

• Consumables
  • Kits and Reagents
  • Others
• Instruments
  • Filtration Systems
  • Chromatography Systems
• Services

Consumables hold the largest market share

The market for consumables in the virus filtration industry is experiencing substantial growth, driven by the recurring need for filtration consumables, such as membranes, cartridges, and cassettes in the pharmaceutical manufacturing process. Unlike capital equipment that has a long lifecycle, consumables are used in a single manufacturing cycle and need frequent replacement, ensuring a consistent demand. Furthermore, the increasing adoption of single-use technologies, particularly in bioprocessing, amplifies the need for disposable filtration consumables, which are viewed as more convenient and less prone to cross-contamination. In addition, regulatory bodies are continually tightening the guidelines for viral safety in biopharmaceutical products, which, in turn, necessitates the use of high-quality consumables that meet these stringent standards. Moreover, the growing development and manufacturing of vaccines and therapies, especially during global health crises, including pandemics, drastically increase the consumption of these disposable products.

Breakup by Application:

• Biologicals
  • Vaccines and Therapeutics
  • Blood and Blood Products
  • Cellular and Gene Therapy Products
  • Others
• Medical Devices
• Water Purification
• Air Purification
• Others

Biologicals account for the majority of the market share

The biologicals segment is a key application area driving the market, primarily due to the rising demand for biotherapeutic products, such as monoclonal antibodies, vaccines, and gene therapies. These complex molecules are produced in living cells, making them vulnerable to viral contamination, thereby necessitating robust filtration processes. Along with this, regulatory scrutiny over the safety of biological products is intensifying, with agencies mandating rigorous viral clearance steps. These regulatory imperatives enforce stringent quality controls, propelling the adoption of advanced virus filtration technologies in the biologicals domain. In addition, the increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune conditions has also amplified the need for biotherapeutic treatments. Moreover, pharmaceutical companies are ramping up their production capacities and implementing state-of-the-art filtration methods to meet both consumer demand and regulatory requirements.

Breakup by End Use:

• Biopharmaceuticals and Biotechnology Companies
• Contract Research Organizations
• Academic Institutes and Research Laboratories
• Others

Biopharmaceuticals and biotechnology companies hold the largest market share

The escalating demand for biopharmaceuticals and the rapid growth of biotechnology companies serve as pivotal market drivers in the virus filtration industry. These entities are at the forefront of developing complex biological products such as monoclonal antibodies, vaccines, and recombinant proteins, which are inherently susceptible to viral contamination. Additionally, the imperative for ensuring product safety and efficacy is a scientific necessity and a regulatory mandate. In confluence with this, organizations are setting stringent guidelines that require the application of robust virus filtration processes for quality assurance. As biopharmaceuticals become increasingly central in treating a range of diseases, from chronic conditions to pandemic-related illnesses, the need for effective virus filtration grows proportionally. Furthermore, advancements in biotechnology, such as CRISPR and gene therapy, have further extended the scope and complexity of bioproducts, subsequently amplifying the necessity for advanced virus filtration solutions.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance, accounting for the largest virus filtration market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest segment.

The market in North America is experiencing significant growth, propelled by a favorable environment for industry expansion. One of the leading drivers is the robust presence of global biopharmaceutical companies and advanced research institutions in the region, which necessitates high-quality virus filtration solutions for product safety. Along with this, regulatory frameworks set by agencies are enforcing stringent guidelines on viral clearance, thereby elevating the demand for efficient filtration technologies. In addition, North America has been a pioneer in biotechnological advancements, contributing to the development of new therapies, vaccines, and other bioproducts that require virus filtration.

Besides this, considerable growth in the investment in healthcare research and development is substantial in this region, further fueling the growth of the market. The occurrence of global health crises, such as pandemics, often leads to a rapid scale-up in vaccine and therapeutic production, dramatically increasing the need for reliable virus filtration systems. All these elements converge to make North America a strong market for virus filtration technologies, driving both innovation and adoption in the industry.

Competitive Landscape:

The key players are continually working on developing more efficient and reliable filtration technologies. This includes innovations in filter membranes, filtration systems, and single-use technologies to provide better solutions to clients. Along with this, the major companies are offering products and services that meet or exceed these regulations, often providing robust validation support for their customers. In addition, companies are entering into strategic partnerships or acquisitions to expand their geographical reach and product portfolio. Apart from this, several brands are offering consultancy services alongside their products to help customers optimize their filtration processes, which is acting as another growth-inducing factor. With an increasing focus on environmental responsibility, some companies are exploring and developing more sustainable filtration technologies, such as reusable or recyclable filter components.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Asahi Kasei Medical Co. Ltd.
• Charles River Laboratories Inc.
• Clean Cells
• Danaher Corporation
• Merck KGaA
• Sartorius AG
• Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

• 1.What was the size of the global virus filtration market in 2024?
• 2.What is the expected growth rate of the global virus filtration market during 2025-2033?
• 3.What are the key factors driving the global virus filtration market?
• 4.What has been the impact of COVID-19 on the global virus filtration market?
• 5.What is the breakup of the global virus filtration market based on the product?
• 6.What is the breakup of the global virus filtration market based on the application?
• 7.What is the breakup of the global virus filtration market based on the end use?
• 8.What are the key regions in the global virus filtration market?
• 9.Who are the key players/companies in the global virus filtration market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Virus Filtration Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Consumables
  • 6.1.1 Market Trends
  • 6.1.2 Major Types
    • 6.1.2.1 Kits and Reagents
    • 6.1.2.2 Others
  • 6.1.3 Market Forecast
• 6.2 Instruments
  • 6.2.1 Market Trends
  • 6.2.2 Major Types
    • 6.2.2.1 Filtration Systems
    • 6.2.2.2 Chromatography Systems
  • 6.2.3 Market Forecast
• 6.3 Services
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Application

• 7.1 Biologicals
  • 7.1.1 Market Trends
  • 7.1.2 Major Types
    • 7.1.2.1 Vaccines and Therapeutics
    • 7.1.2.2 Blood and Blood Products
    • 7.1.2.3 Cellular and Gene Therapy Products
    • 7.1.2.4 Others
  • 7.1.3 Market Forecast
• 7.2 Medical Devices
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Water Purification
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Air Purification
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End Use

• 8.1 Biopharmaceuticals and Biotechnology Companies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Contract Research Organizations
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Academic Institutes and Research Laboratories
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Asahi Kasei Medical Co. Ltd.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Charles River Laboratories Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Clean Cells
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
  • 14.3.4 Danaher Corporation
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Merck KGaA
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Sartorius AG
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Thermo Fisher Scientific Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis